Overview
- A large retrospective analysis from Penn Medicine of 111,646 overweight or obese women, presented at ASCO and published in JCO, reported roughly 35% lower odds in the full cohort and about 30% lower odds in a matched cohort for incident breast cancer among patients with documented GLP‑1 prescriptions.
- The researchers used electronic health records for women ages 45 to 80 who had breast imaging between 2022 and 2025, and matched GLP‑1 users to non‑users by age, race, BMI, breast density, and diabetes status to reduce bias.
- Investigators note the study is observational and cannot prove causation because it did not separate individual GLP‑1 agents or measure treatment duration, genetic risk, cancer subtype or stage, leaving the possibility of residual confounding.
- Authors say biological plausibility exists—GLP‑1 drugs drive substantial weight loss, reduce inflammation and alter insulin and metabolic pathways—and these mechanisms could plausibly lower postmenopausal breast cancer risk.
- Penn is planning a multisite randomized clinical trial to test causation and identify which women, which drugs, and what treatment duration might work if the association is confirmed, with implications for cost, long‑term safety and access if trials are positive.